The latest data reveals which pathogens are the biggest killers and which regions and populations suffer disproportionately. Based on this information, we’ve built a portfolio of treatments at the intersection of: priority diseases, notably sepsis and sexually transmitted infections; priority pathogens for which few treatments exist; and key regions and populations, including pregnant women, children and the elderly, who are hardest hit by AMR. By developing and making accessible antibiotic treatments that target these areas, we can maximize our public health impact.

Antibiotic resistance kills millions of lives each year and leads to even more suffering and illness. Healthcare systems and economies also take a hit. The Global Leaders Group has projected that AMR could result in up to US$412 billion worldwide per year in healthcare system costs by 2035. It could also lead to $433 billion in lost revue per year due to reduced workforce participation. In contrast, a comprehensive intervention to counter AMR, including investment in the development in new antimicrobials, could return US$13 for every US$1 spent. There is no doubt that smart investments in efforts to counter AMR now will pay themselves back many times over.

With targeted investment from donors, GARDP has enabled the development of new antibiotic treatments and combinations of existing antibiotics in an extremely cost-effective way. Our unique R&D and access model has built-in cost-saving measures, including pooling knowledge and resources with our extensive network of partners and alliance with DNDi. The model has proven to offer excellent value for money, for example in the co-development of zoliflodacin to treat multidrug-resistant gonorrhoea. We estimate that GARDP’s total cost to develop this first-in-class treatment will amount to approximately €80 million, significantly less than the average estimated cost to develop any type of antibiotic treatment.

To achieve our goal of developing a pipeline of priority antibiotic treatments while strengthening the overall ecosystem for R&D and access, we must ensure that every part of the GARDP model is funded.

Core, unrestricted funding allows us to take a strategic approach to our financial and operational planning. This timely, predictable, and flexible funding is indispensable to respond to the priorities outlined in the Global Action Plan on Antimicrobial Resistance and to take advantage of new opportunities that align with our strategy and offer exceptionally good value in terms of impact.

As we embark on a new strategic phase (2024-2028), we invite to you invest in GARDP to:

• Deliver greater success and identify and advance new drugs to tackle antibiotic-resistant infections.  

• Strengthen the global antimicrobial R&D ecosystem to better ensure future global health security 

• Sustain progress made thus far on the Sustainable Development Goals. 

By working in partnership, we can fix the public health failure by prioritizing the right antibiotics for development and making them available to the people who need them.